These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 10218450)

  • 1. The HER-2/neu story: from oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy.
    Mehigan BJ; Kerin MJ
    Eur J Surg Oncol; 1999 Apr; 25(2):111-2. PubMed ID: 10218450
    [No Abstract]   [Full Text] [Related]  

  • 2. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laminin, Her2/neu and Ki-67 as prognostic factors in non-small cell lung cancer.
    Szelachowska J; Jeleń M
    Rocz Akad Med Bialymst; 2004; 49():256-61. PubMed ID: 15631353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HER-2/neu oncogene as prognostic factor in breast carcinoma].
    Colnaghi MI
    Pathologica; 1992; 84(1094):55-6. PubMed ID: 1363757
    [No Abstract]   [Full Text] [Related]  

  • 5. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
    Prowell TM; Armstrong DK
    Semin Oncol; 2006 Dec; 33(6):681-7. PubMed ID: 17145348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
    Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
    Serrano-Olvera A; Dueñas-González A; Gallardo-Rincón D; Candelaria M; De la Garza-Salazar J
    Cancer Treat Rev; 2006 May; 32(3):180-90. PubMed ID: 16483720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efforts aimed at reducing noise, data overload in microarrays.
    Tuma RS
    J Natl Cancer Inst; 2005 Aug; 97(16):1173-5. PubMed ID: 16106018
    [No Abstract]   [Full Text] [Related]  

  • 10. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
    Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometry: a new approach for the molecular profiling of breast cancer.
    Lostumbo A; Mehta D; Setty S; Nunez R
    Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
    Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
    Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
    Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of molecular genetic analysis in selecting antitumor therapy].
    Imianitov EN; Moiseenko VM
    Vopr Onkol; 2008; 54(2):121-32. PubMed ID: 18522159
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.
    Vitetta ES; Uhr JW
    Cancer Res; 1994 Oct; 54(20):5301-9. PubMed ID: 7923157
    [No Abstract]   [Full Text] [Related]  

  • 19. Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein.
    Dougall WC; Greene MI
    Cell Biophys; 1994; 24-25():209-18. PubMed ID: 7736525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer trials get set for biomarkers.
    Bouchie A
    Nat Biotechnol; 2004 Jan; 22(1):6-7. PubMed ID: 14704688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.